Clinical Trials Directory

438 clinical trials found.
Skin Cancer - Melanoma

We are doing this study to find out if an experimental drug called V940 (the study drug) is a safe and effective option for melanoma patients who have had surgery when it is given in combination with pembrolizumab. We want to know how well the study drug compares to pembrolizumab taken on its own.

Compensation: No
Oncology
Brain, Spinal Cord and Nerves

We are doing this study to find out if an experimental drug called CVN424 (the study drug) can help people diagnosed with advanced Parkinson's Disease (PD) who are on a stable dose of medication and continue to experience three of more hours of "OFF-time." OFF-time is a term that refers to the time when people experience PD symptoms between doses of medicine. We want to know if the study drug can reduce symptoms and lower that amount of time.

Compensation: Yes
Ages: 30-110
Non-Oncology
Other
Hematologic Malignancies and Cellular Therapy

We are doing this study to find out if continued use of an experimental drug called bomedemstat (the study drug) can provide an extended benefit for people with myeloproliferative neoplasms. We are enrolling people who have been in a previous study using the study drug and received a positive benefit.

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital
Hematologic Malignancies and Cellular Therapy

We are doing this study to find out if an investigational drug called fostamatinib (the study drug) is beneficial for cGvHD when it is used in combination with a standard of care drug, ruxolitinib. We want to know if the study drug can improve relief from cGvHD symptoms.

Compensation: No
Oncology
Eyes and Vision

We are doing this study to find out if an investigational drug called tinlarebant (the study drug) is safe and useful for treating geographic atrophy (GA).

Compensation: Yes
Ages: 60-85
Non-Oncology
Duke University Hospital
Phase I

We are doing this study to find out if an experimental drug called PHTS001 (the study drug) is a safe and effective option for people who have advanced relapsed or refractory solid tumors.

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital
Breast Cancer

We are doing this study to find out if the combination of two hormonal drugs, giredestrant and fulvestrant, are a safe and effective option if they are given with the study doctor's choice of a class of medicines called CDK4/6 inhibitors to people who have ER-positive, HER2-negative breast cancer that is resistant to standard treatments.

Compensation: No
Oncology
Bones, Joints and Muscles

We are doing this study to find out what factors affect how well platelet rich plasma (PRP) injections work for people who choose to get them to treat a problem with their hip, knee, or shoulder joint. We hope the information we get from this study will help us find out what effects, if any, factors like age, gender, medical conditions, or injury history have on the outcomes of these injections.

Compensation: No
Ages: 18-110
Non-Oncology
Other